ImmunityBio faces securities fraud probe over Anktiva drug claims
Lowey Dannenberg P.C. has launched an investigation into ImmunityBio Inc. over possible breaches of federal securities laws. The national law firm, which specialises in corporate fraud and antitrust cases, filed a complaint against the company and one of its officers on March 26, 2026. The investigation centres on claims that ImmunityBio misled investors about Anktiva, one of its key products. According to the complaint, the company allegedly failed to disclose important details and made misleading statements about the drug’s capabilities.
Lowey Dannenberg has a long track record in handling high-stakes financial litigation. The firm has recovered billions of dollars for investors in past cases and frequently prosecutes multi-million-dollar lawsuits. Their focus now is on whether ImmunityBio and its executives provided full and accurate information to shareholders. The complaint marks the latest legal challenge for ImmunityBio, which has faced scrutiny over its public disclosures in recent years. The firm’s investigation will examine whether the company’s statements complied with securities regulations.
The outcome of this case could have financial and reputational consequences for ImmunityBio. If violations are confirmed, the company and its executives may face penalties or further legal action. Investors are awaiting developments as the investigation proceeds.
